Abstract
The strategy in the treatment of metastatic renal cell carcinoma (MRCC) is based on prognostic factors for survival. General performance status, delay from the diagnosis of primary tumor to occurrence of metastases, number of metastatic sites or site of metastases (lung, liver) and biological changes such as hemoglobin value, calcium value, and sedimentation rate are reported as the most predictive factors for survival. The first line of treatment in MRCC is immunotherapy for the majority of patients. Disagreement remains regarding the choice of immunotherapy: interleukin-2 (IL-2) and/or interferon alpha; and the mode of administration of IL-2: intravenous or subcutaneous route. Major therapeutic changes are coming with new drugs directed against new targets. Bevacizumab, an anti-Vascular Endothelial Growth Factor (VEGF) has been approved in second-line treatment. Other compounds are under investigation such as drugs targeting the EGF and Ras pathways.
Keywords: biphosphonates, immunotherapy, anti-angiogenic therapy, metastatic sites, nephrectomy, fluorouracile, cardiac toxicity, antitumoral activity, interferon (ifn)
Current Cancer Therapy Reviews
Title: Current Strategy in the Treatment of Metastatic Renal Cell Carcinoma
Volume: 1 Issue: 2
Author(s): Alain Ravaud, Marie-Sarah Dilhuydy, Aimery Huchet, Stephane Pedeboscq and Jean-Philippe Maire
Affiliation:
Keywords: biphosphonates, immunotherapy, anti-angiogenic therapy, metastatic sites, nephrectomy, fluorouracile, cardiac toxicity, antitumoral activity, interferon (ifn)
Abstract: The strategy in the treatment of metastatic renal cell carcinoma (MRCC) is based on prognostic factors for survival. General performance status, delay from the diagnosis of primary tumor to occurrence of metastases, number of metastatic sites or site of metastases (lung, liver) and biological changes such as hemoglobin value, calcium value, and sedimentation rate are reported as the most predictive factors for survival. The first line of treatment in MRCC is immunotherapy for the majority of patients. Disagreement remains regarding the choice of immunotherapy: interleukin-2 (IL-2) and/or interferon alpha; and the mode of administration of IL-2: intravenous or subcutaneous route. Major therapeutic changes are coming with new drugs directed against new targets. Bevacizumab, an anti-Vascular Endothelial Growth Factor (VEGF) has been approved in second-line treatment. Other compounds are under investigation such as drugs targeting the EGF and Ras pathways.
Export Options
About this article
Cite this article as:
Ravaud Alain, Dilhuydy Marie-Sarah, Huchet Aimery, Pedeboscq Stephane and Maire Jean-Philippe, Current Strategy in the Treatment of Metastatic Renal Cell Carcinoma, Current Cancer Therapy Reviews 2005; 1 (2) . https://dx.doi.org/10.2174/1573394054021709
DOI https://dx.doi.org/10.2174/1573394054021709 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Anti-Cancer Charm of Flavonoids: A Cup-of-Tea Will Do!
Recent Patents on Anti-Cancer Drug Discovery Trends in the Exploration of Anticancer Targets and Strategies in Enhancing the Efficacy of Drug Targeting
Current Molecular Pharmacology The Anti-Cancer Effect of A3 Adenosine Receptor Agonists: A Novel, Targeted Therapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Genetic Predisposition to Parkinson’s Disease and Cancer
Current Cancer Drug Targets Novel MicroRNA Binding Site SNPs and the Risk of Clear Cell Renal Cell Carcinoma (ccRCC): A Case-Control Study
Current Cancer Drug Targets Integrin (αvβ3) Targeted RGD Peptide Based Probe for Cancer Optical Imaging
Current Protein & Peptide Science Sesterterpenoids with Anticancer Activity
Current Medicinal Chemistry SAGE Application in the Study of Diabetes
Current Pharmaceutical Biotechnology Ototoxicity: Mechanisms of Cochlear Impairment and its Prevention
Current Medicinal Chemistry Pharmacokinetics of CNT-based Drug Delivery Systems
Current Drug Metabolism Signs and Related Mechanisms of Ethanol Hepatotoxicity
Current Drug Abuse Reviews The Extracellular Matrix Regulates Cancer Progression and Therapy Response: Implications for Prognosis and Treatment
Current Pharmaceutical Design The Role of Prostaglandins in Liver Ischemia-Reperfusion Injury
Current Pharmaceutical Design Organoids: Current Implications and Pharmaceutical Applications in Liver Diseases
Current Molecular Pharmacology Strategies for the Biological Evaluation of Gold Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Hepatocarcinogenesis and Ceramide/Cholesterol Metabolism
Anti-Cancer Agents in Medicinal Chemistry Novel Inflammatory Indices in Aortic Disease
Current Medicinal Chemistry In vivo Near-infrared Fluorescence Tumor Imaging Using DiR-loaded Nanocarriers
Current Drug Delivery Targeting Strategies for Renal Cancer Stem Cell Therapy
Current Pharmaceutical Design ABC Transporter Inhibitors in Reversing Multidrug Resistance to Chemotherapy
Current Drug Targets